Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan C Zhao

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Nature Communications|February 7, 2018
BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1Sen Zhu, Dongyu Zhao, Lin Yan, et al.
Nature Genetics|April 26, 2022
HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancerXiaodong Lu, Ka-Wing Fong, Galina Gritsina, et al.
Cell Reports|March 9, 2017
CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon ResponseAbdul S Qadir, Paolo Ceppi, Sonia Brockway, et al.
Cancer Research|May 17, 2020
Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Cancer Research|April 7, 2019
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Science Advances|April 8, 2021
Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancerSu H Park, Ka-Wing Fong, Jung Kim, et al.
Nature Communications|March 28, 2026
FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironmentLourdes Brea, Hongshun Shi, Viriya Keo, et al.
The Journal of Clinical Investigation|February 28, 2017
Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosisLaure Gilles, Ahmet Dirim Arslan, Christian Marinaccio, et al.
Oncogene|January 7, 2026
EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2Wanqing Xie, Qi Chu, Lourdes Brea, et al.
The Journal of Clinical Investigation|November 18, 2025
EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathwayYang Yi, Joshua Fry, Chaehyun Yum, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Nature Communications|February 7, 2018
BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1Sen Zhu, Dongyu Zhao, Lin Yan, et al.
Nature Genetics|April 26, 2022
HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancerXiaodong Lu, Ka-Wing Fong, Galina Gritsina, et al.
Cell Reports|March 9, 2017
CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon ResponseAbdul S Qadir, Paolo Ceppi, Sonia Brockway, et al.
Cancer Research|May 17, 2020
Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Cancer Research|April 7, 2019
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
Science Advances|April 8, 2021
Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancerSu H Park, Ka-Wing Fong, Jung Kim, et al.
Nature Communications|March 28, 2026
FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironmentLourdes Brea, Hongshun Shi, Viriya Keo, et al.
The Journal of Clinical Investigation|February 28, 2017
Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosisLaure Gilles, Ahmet Dirim Arslan, Christian Marinaccio, et al.
Oncogene|January 7, 2026
EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2Wanqing Xie, Qi Chu, Lourdes Brea, et al.
The Journal of Clinical Investigation|November 18, 2025
EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathwayYang Yi, Joshua Fry, Chaehyun Yum, et al.
Pageof 4